I am done with this board. Bunch of kids and idiots (not all of you). I will continue to post scripts and analyst comments on stock twits. For the record, the script numbers are from Symphony, one of the two major providers along with IMS which I get via our Bloomberg terminal (no they are not available on the Bloomberg website, only on the institutional terminal. So to the dimwits here there is no link any more than there is a link to analyst notes from our institutional service. Stocktwits is free so there's no reason why anyone interested here can't get them there. It's very easy there because you can follow people so you will get all their posts.
Senators introduce regenerative medicine bill • 1:40 PM
Senators Barbara Boxer ((D-CA)) and Mark Kirk ((R-IL)) introduce legislation that will establish a national strategy to support regenerative medicine (RM) research.
Among the requirements of the Regenerative Medicine Promotion Act are: a report by the GAO identifying all ongoing federal programs and activities pertaining to RM, the establishment of a Regenerative Medicine Coordinating Council and the maintenance of a national strategy for the promotion of RM R&D.
Companies involved in the space include (ONVO) (HART) (CUR) (CYTX) (STEM) (ATHX)
Let me try to explain something to you as an attorney. There are many other SEC rules a public company can violate besides management selling stock in their personal account when they shouldn't be. This is one example. The company pumped the stock prior to selling stock to the public which helped the company raise more money. Yes, there are rules against this and though securities law is not my niche I suspect CYTR and GALE's outside legal counsel are licking their chops on the fees they will be earning defending these companies on this one.
ajohnke, you are also missing the point. I have been in management at public companies for 25 years. Do we use a PR firm? Sure/ Reputable companies use PR firms to help get them coverage with analysts, get the company in the paper, in journals etc. Would any company I have been involved with hire a schlock outfit to pen articles in something like SA using fake names to hype our company? Absolutely not. That is an act of a company that doesn't believe the company's story can 'sell itself" and more concerned about short term stock price and long term operations. So what did all the pumping done by this "PR firm" accomplish for CYTR? Stock is right back in the $3s and the company has lost credibility with the street. And worse, as an attorney I hate these law firms that file a lawsuit anytime a stock drops. Most are bogus, like suits brought when pharma announced that a drug trial has been halted by FDA because of a health risk. Duh, that is the purpose of a trial, to see if a drug is effective and if it is safe. How can you sue a company because the trial determined it is not safe? However, in my opinion, I think the law firms may have a bona fide case here for violation of SEC rules. I suspect there were some rules broken here in terms of disclosures. If there is an independent board here, and not sure there is, the CEO any anyone who knew about what this PR firm was doing needs to be terminated..
peter, you don't get it do you (and I still own part of my position here which I wish I had sold). REAL companies don't have to resort to #$%$ like this, i.e. hiring sleezy firms to pump their stocks on message boards and websites like SA and others. REAL CEOs focus on running and their businesses. if the drug is legit it will be huge and the stock will take care of itself. The sleezy actions highlighted in the terrific SA article call into question everything the company has said about their prospects. management that would stoop to these levels are capable of anything. Get it?
ik4763, you mean in your humble opinion of one. As I told folks about AMRN, NEVER ignore what the market is telling you about a stock or a company's prospects. The smart money isn't always right but is more often than not and right now SNSS market cap is 5X that of CYCC so the street does not share your thoughts that CYCC's drug is better. Don't fall in love with an investment.
I am not concerned. market rolled again this afternoon and looks like the sector as well
The writer responded to my post and at least admitted that he must have taken the wrong revenue for MDXG..he said he pulled it from Google Finance. I suggested that if he is going to publish articles, he might want to pull financial information from the singular source that can be relied on, 10Ks and 10Qs.
Sales from products for 2013 $35 million higher for MDXG than OSIR, $59 million vs $24 million and the author says $3 million? New math? LOL
Correct. OSIR lost money for 2013 from continuing ops and two analyst have them losing i think 23 cents per share in 2014. MDXG analysts have them losing one penny this year but I look for that to be revised to be positive
LOL tiny. Tell that to AMZN sporing a $140 billion market cap with no profits to show. The market doesn't care because it recognizes that AMZN is building its business and that profits will come later in leaps and bounds as it will for MDXG. Right now in the growth phase its about revenue growth and dominating the space as MDXG is starting to do.